WCN24-1776 NEFECON EFFECT ON QUALITY OF LIFE IN PATIENTS WITH IgAN: SF-36 RESULTS FROM THE PHASE 3 NeFIgArd TRIAL

Схожі ресурси

• WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL
  за авторством: Jonathan Barratt, та інші
  Опубліковано: (2024-04-01)
• WCN24-1776 NEFECON EFFECT ON QUALITY OF LIFE IN PATIENTS WITH IgAN: SF-36 RESULTS FROM THE PHASE 3 NeFIgArd TRIAL
  за авторством: Jonathan Barratt, та інші
  Опубліковано: (2024-04-01)
• WCN24-1674 NEFECON TREATMENT RESPONSE IN ASIAN AND WHITE PATIENT POPULATIONS WITH IMMUNOGLOBULIN A NEPHROPATHY: A 2YEAR ANALYSIS OF THE PHASE III NEFIGARD TRIAL
  за авторством: Jonathan Barratt, та інші
  Опубліковано: (2024-04-01)
• WCN25-1898 IMPLICATIONS OF PROTEINURIA REMISSION ON ESTIMATED GLOMERULAR FILTRATION RATE (eGFR) TRAJECTORY IN PATIENTS (Pts) WITH IgA NEPHROPATHY (IgAN) IN PROTECT
  за авторством: Bruce Hendry, та інші
  Опубліковано: (2025-02-01)
• WCN25-2470 Long-term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgAN
  за авторством: Vivekanand Jha, та інші
  Опубліковано: (2025-02-01)